|
Wednesday 19th January 2022 |
Text too small? |
At a Special Meeting held online today, Wednesday 19 January 2022, Rua Bioscience shareholders voted in favour of Rua acquiring Zalm Therapeutics. Shareholders were asked to vote on a resolution being:
That the issue of:
• 8,140,000 new ordinary shares (Initial Shares); and
• 16,280,000 equity securities having the right to convert into ordinary shares on achievement of the milestones described in the explanatory notes (Performance Shares) to the shareholders of Zalm Therapeutics Limited (which may together eventually result in those subscribers holding 28,735,632 fully paid ordinary shares in the Company) be approved for all purposes, including for the purposes of NZX Listing Rule 4.2.1(a).
As required by NZX Listing Rule 6.1, all voting was conducted by a poll. The resolution was passed by the required majority, and the result of the voting is attached.
Please see the link below for details
Source: Rua Bioscience Limited
No comments yet
TGG - FY 2025 Earnings Guidance Update
Meridian Energy monthly operating report for December 2025
January 21st Morning Report
PEB - Q3 26 Results and Key Strategic Milestones
FBU - Fletcher Building announces sale of Fletcher Construction
A thank you from Stuff's owner and publisher
FPH Appoints New Director and Future Director
January 19th Morning Report
January 15th Morning Report
January 14th Morning Report